Fedratinib Hydrochloride

US Brand Name(s)Inrebic

Use of Fedratinib Hydrochloride in Cancer Treatment

Adults can use Fedratinib Hydrochloride to treat the following conditions:

  • Intermediate-2 or high-risk myelofibrosis (a bone marrow disease), comprising the following types:
  • Primary myelofibrosis is a kind of myelofibrosis.
  • Myelofibrosis after polycythemia vera.
  • Post-essential thrombocythemia causes Myelofibrosis.

Fedratinib hydrochloride is also under investigation for use in the treatment of various diseases.

Definition:

The monohydrate hydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets, binds to and inhibits the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.

Furthermore, fedratinib targets, binds to, and inhibits FLT3 activity. This inhibits uncontrolled FLT3 signalling, which prevents tumour cells overexpressing FLT3 from proliferating. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in the majority of B-lineage neoplasms and acute myeloid leukemias, and it is involved in tumour cell proliferation.

Fedratinib Hydrochloride  – MedlinePlus Information – A summary of key facts regarding this medication in layman’s terms, which may contain the following:

  • this drug’s cautionary statements,
  • What is the purpose of this medication and how to use it?
  • What you should inform your doctor about this medication before using it?
  • Things you should know about this medication before taking it
  • Additional medications that might interact with this one
  • Adverse consequences that might occur

Experts are frequently investigating drugs to see whether they can treat or prevent conditions other than those with authorization. This patient information leaflet only covers authorized uses of the medications. However, much of the material might also apply to unapproved uses which are under investigation.